ArticleFuture oncology (London, England)2025

IDeate-Lung02: a Phase 3 study of second-line ifinatamab deruxtecan in patients with relapsed small cell lung cancer.

Taofeek K Owonikoko et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.